Kamada Ltd at H.C. Wainwright: Strategic Growth and Expansion

Kamada Ltd. (NASDAQ:KMDA) presented a robust financial outlook at the H.C. Wainwright 27th Annual Global Investment Conference, projecting current year revenue of $190 million and EBITDA growth to 22-23%, alongside an 11% gross profit increase and 58% EPS growth. The specialty plasma therapeutics company is pursuing aggressive growth strategies, including active M&A targeting commercial-stage assets, expanding its U.S. and MENA market presence, and leveraging new plasma collection centers expected to contribute significantly. A key future catalyst is its inhaled Alpha-1 Antitrypsin (AAT) therapy, currently in Phase 3 trials for a $2 billion market, with interim analysis results anticipated by year-end, positioning Kamada for substantial potential expansion.

Analysis

Kamada Ltd. (KMDA) has presented a compelling growth narrative underpinned by strong financial execution and a multi-faceted expansion strategy. The company is on track to meet its $190 million revenue guidance for the current year, having generated $89 million in the first half. More significantly, management projects a dramatic expansion in EBITDA margin from 6% to approximately 22%-23%, supported by an 11% increase in gross profit and a 58% rise in EPS in the first six months. This growth is driven by a combination of organic expansion, with its Kedrab product capturing 50% of the U.S. market, and strategic initiatives including M&A and vertical integration. Kamada is actively pursuing commercial-stage acquisitions to accelerate growth into 2026 and is operationalizing two new plasma collection centers, each expected to add $8 to $10 million in annual revenue at peak capacity. The most significant potential catalyst is the inhaled Alpha-1 Antitrypsin (AAT) therapy, currently in a Phase 3 trial targeting a $2 billion market. A pivotal interim analysis is expected by year-end, with the trial's statistical success hurdle notably lowered by the FDA's agreement to a 0.1 p-value for the primary endpoint, a detail that de-risks the outcome to a degree.

Key Decisions for Investors

• Investors should recognize the strong fundamental momentum, evidenced by significant EBITDA margin expansion and a 58% EPS increase, which supports the company's current valuation and positive outlook.
• The primary focus should be the upcoming year-end interim analysis of the Phase 3 inhaled AAT trial; a positive result represents a major transformative catalyst, while the FDA's acceptance of a 0.1 p-value provides a more favorable statistical pathway to success.
• Monitor execution on the stated M&A strategy, as a commercial-stage acquisition is a key component of the company's plan to accelerate growth and positively impact 2026 financials.
• Given the stock's recent 13% gain, investors should be mindful that high expectations are being priced in, and the position carries significant event risk tied to the AAT trial outcome and potential M&A announcements.